Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative apatinib plus XELOX with or without camrelizumab for resectable gastric cancer
ChiCTR2100042385Phase 4Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib, camrelizumab, capecitabine and oxaliplatin in gastric cancer (GC) (2 cohorts), sponsored by Tangdu Hospital. Primary endpoint: Pathologic response rate. Started Jan 2021; status: recruiting.
02
Drugs
Rivoceranibcamrelizumabcapecitabineoxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2100042385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042385.